2025 Labelling Packaging 
European Pharmaceutical Review
NOVEMBER 1, 2024
The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12 billion in 2025 to approximately $174.45 billion by 2033, according to a study published by Towards Packaging. Specifically, the “high quality of biodegradable and recyclable packaging materials” are driving the market.
European Pharmaceutical Review
AUGUST 30, 2023
The agreement stipulates that certain conditions must be met in the labelling and packaging of these medicinal products. The following new measures are set to be introduced on 1 January 2025. After this date: Under the framework, medicines can have the same packaging and labelling across the UK.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmafile
JANUARY 23, 2025
Award winners by category DELIVERY AND DEVICE INNOVATION SHL Medical for Elexy reusable electromechanical autoinjector ECO-DESIGN WINNER Huhtamaki for Omnilock Ultra PAPER PACKAGING INNOVATION WINNER Mitsubishi Gas Chemical Company for new OXYCAPT Multilayer Plastic Vial PATIENT-CENTRIC DESIGN WINNER UCB Pharma for Bimzelx 160mg 2ml autoinjectors product (..)
LifeProNow
JANUARY 18, 2025
January 15, 2025 : “Johnson & Johnsonannounced it has initiated the submission of an original New Drug Application with the U.S. It is placed into the bladder by a healthcare professional using a co-packaged urinary placement catheter in an outpatient setting in under five minutes and without the need for anesthesia.
European Pharmaceutical Review
AUGUST 17, 2022
The second facility for WuXi STA in the US, Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.
Pharmaceutical Technology
APRIL 21, 2023
While the FDA sent Lilly a complete response letter detailing issues pertaining to the proposed manufacturing of mirikizumab, the regulator raised no concerns about the clinical data package or label for the medicine. The recent setback dents mirikizumab’s chances to be the first among the IL-23 inhibitors to launch in the US for UC.
PharmaShots
JUNE 1, 2023
We are conducting an open-label, dose-escalation, phase I/II study PDC-LUNG-101 assessing the safety, tolerability, immunogenicity, and the preliminary clinical activity of therapeutic cancer vaccine PDC*lung, associated or not with anti-PD1 treatment in patients with non-small-cell lung cancer (NSCLC).
Expert insights. Personalized for you.
52 
Let's personalize your content